

Treatment of Alcohol Related Liver Disease (ARLD) by Acute Trusts in Wessex

A report for Wessex AHSN 'Reducing Harm from Alcohol' Programme

Dr Brad Keogh Dr Anastasios Argyropoulos Centre for Implementation Science

A.Argyropoulos@soton.ac.uk

Wessex AHSN alcohol programme clinical leads: Dr Julia Sinclair & Dr Leonie Grellier Wessex AHSN senior programme manager: Kathy Wallis

alcohol@wessexahsn.net

Contents

- Introduction & key findings: Pages 3-5
- Headline figures & trends over time: pages 6-9
- Patient survival, demographics, repeat attendances & length of stay: pages 10-13
- Variation across Wessex Acute Trusts: pages 14-18
- Variation across Wessex CCGs: pages 19-20
- Estimations of cost avoidance from earlier intervention: pages 21-25
- What must YOU do now? pages 26-28
- Appendix A: Data limitations page 29
- Appendix B: Liver Disease ICD-10 codes pages 30-32
- Appendix C: Alcohol-specific ICD-10 codes page 33
- Appendix D: Estimating early intervention cost avoidance in Wessex pages 34-40

2

Key findings in Wessex

Data from the 9 Acute NHS Trusts in Wessex shows:


- The number of Liver Disease admissions are increasing each year
- In 2015: Across Wessex an average of **38% of Liver Disease admissions** were for **alcohol-specific** conditions, this increased to **46%** at one Acute Trust
- Alcohol Related Liver Disease (ARLD) patients are on average 10 years younger and more likely to be male
- The probability of death for an ARLD diagnosed patient 3-years after diagnosis is 47%, compared with 28% for a non-ARLD patient*
- ARLD patients have a greater number of admissions and longer lengths of stay than other Liver Disease patients
- An **audit** from Hampshire Hospitals Foundation Trust suggests that at least an additional **13%** of Liver Disease admissions have alcohol use disorders but are not coded as such. Further audits are being completed at other Trusts across Wessex
- It is estimated that improving patient management in Acute Trust settings could save at least £12.9m-£17.2m per year** across the 9 Acute Trusts

* Figures based on Trust recorded data only, hence probability of death may be under-reported here

**Range determined by ARLD diagnosis either 1 or 2 years earlier

Development of regional Wessex acute Liver Disease (LD) database

- 9 Wessex Acute Trusts have contributed admissions data to a regional Wessex database
- The database comprises all LD admissions Jan 2011 Dec 2015: ~32,500 admission episodes with over 350 data fields for each admission (~11.4 million elements)
- As well as this report there are individual reports available for each Trust/CCG



4

This data does not include:

- Any hospital admission where Liver Disease is not coded (even if present)
- Any admission occurring outside of the 9 Acute Trusts

ARLD and alcohol-specific admissions are underestimated where:

- Patients have **not been screened** for alcohol
- Patients screened but not coded in Trust electronic records
- Patients where ARLD is obscured by obesity-related Liver Disease

Headline numbers: Wessex (9 Acute Trusts)

- During Jan 2011 Dec 2015:
 - There were 26,900 LD admissions
 - There were over 12,000 ARLD admissions (from 5,520 ARLD patients)
 - On average there were ~865 new diagnoses of ARLD per year
 - 40% of all LD admissions had an alcohol-specific condition recorded
 - 85% of all LD admissions were emergency
- Between Jan-Dec 2015:
 - There were 4,860 LD patients
 - Who had 6,400 admissions
 - Of which **2,400** were **alcohol-specific admissions**

- Definitions of admissions: LD: patient with Liver Disease diagnosis ARLD: patient with Alcohol-Related Liver Disease diagnosis Alcohol-specific: admission with ARLD or other alcohol diagnosed conditions For full definitions see Appendix A
- There were 1,620 LD patients who had at least one admission for an alcohol-specific condition
- Of the LD patients there were 1,340 patients diagnosed with ARLD
 - Who had **2,070 admissions**
 - Using 23,000 bed days
 - At a PbR cost of over £5,870,000*

* Cost may be under-reported by up to 10%, as some admissions could not be assigned to a HRG tariff

6


Proportion of Liver Disease admissions ARLD or alcohol-specific in Wessex

Key Narrative

In 2015 in Wessex 38% of LD admissions were coded with an alcohol-specific condition.

In 2015 in Wessex 32% of LD admissions were coded with ARLD.

A HHFT audit suggests that up to an additional 13% of Liver Disease admissions have alcohol use disorders but are not coded as such.



Numbers of Liver Disease admissions in Wessex over time

Key Narrative


In Wessex there were over 6400 LD admissions in 2015 and the no. of LD admissions have increased over time (43% between 2011-15).

ARLD admissions have slightly increased (8% between 2011-15)

The total no. of alcohol-specific admissions ('ARLD' and 'other alcohol') have increased by 14% between 2011-15.

43% of all LD admissions between 2011-2015 were alcohol-specific.

A HHFT audit suggests that up to an additional 13% of Liver Disease admissions have alcohol use disorders but are not coded as such.



No. of Liver Disease admissions are increasing each year Alcohol-specific admissions (ARLD and 'other alcohol') have increased by 14% (2011-15)

8

Admission coding by Liver Disease code in Wessex (final K-code of spell)


Key Narrative

When considering the final LD diagnosis recorded in the hospital spell:

Between 2011-2015 there has been significant increase (164%) in 'Non-alcoholic fatty liver disease' (NAFLD) and 'Non-alcoholic steatohepatitis' (NASH) diagnosed admissions.

Over this time there has also been an increase of 44% in the number of 'other LD' admissions.

These changes are most likely to be due to the increase in obesity.




Impact of alcohol on Liver Disease (2012 cohort)

- 2,970 patients were admitted for LD for the first time in 2012
- Over 4 years (2012-2015) these patients had:
 - 5,110 Admissions
 - 1,309 Deaths (44% died)
- A comparison of those with an ARLD diagnosis and those without is shown below **over the 4 year period**:


	ARLD		Non-ARLD						
86	3 Patients (29% of cohort)	2107 Patients (71% of cohort)						
2,2	282 Admissions (45% of co	ohort admissions)	2,828 Admissions (55% of cohort admissions)						
	6 Admissions per patient c edian)	on average	1.3 Admissions per patient on average (median)						
42	8 Deaths (49.6% died)		881 Deaths (42% died)						
	ARLD patients have a greater number of admissions on average		6.7% of LD patients not diagnosed with ARLD had at least 1 alcohol-specific admission						
	than other Liver Disease patients								

ARLD patient demographics in Wessex (2012 cohort)

ARLD coded patient population in Wessex (2012)



Non-ARLD coded patient population in Wessex (2012)



Key Narrative

Patients admitted with an ARLD code are on average younger than those without (median age: 57yrs compared with 67yrs).

Patients admitted with an ARLD code are more likely to be male (68% of ARLD group) that those without (50% male in non-ARLD group).

Liver Disease survival in Wessex: 2012 cohort, ages 46-65 years


Key Narrative

Based on those admitted for the first time with a LD diagnosis in 2012 (age 45-65):

The probability of a LD patient surviving after first diagnosis (of any LD) in Wessex is much lower for those who have ARLD diagnosed.

Within 4 years of first LD diagnosis the probability of death for an ARLD diagnosed patient is 49%, compared with 28% for a non-ARLD patient.

Note: deaths only include those recorded on Trust data systems.




Liver disease Length of Stay in Wessex (46-65 yrs)

Key Narrative

When comparing the most common ARLD age group (46-65yrs) difference in length of stay (LOS) is greater on average by 3 days (7 days rather than 4). Longer LOS are also seen in the 26-45, 66-75 & 76-85yrs age groups.

There are likely to be undiagnosed ARLD patients in the non-ARLD group, hence the difference in LOS may be even greater than that shown here.



Trust variation: number of Liver Disease admissions at Trusts across Wessex

Key Narrative

Number of admissions varied between Trusts in 2015. There were almost 1,800 LD admissions at University Hospital Southampton FT in 2015.

There were over 850 admissions for ARLD at University Hospital Southampton FT and Portsmouth Hospitals Trust in 2015.

A HHFT audit suggests that up to an additional 13% of LD admissions could be coded with alcohol if correctly written in notes.


Admission numbers of ARLD, other alcohol & other LD, by Trust, in Wessex (2015) 1800 ARLD 1600 other alcohol other LD 1400 no. of admissions 1200 1000 800 600 400 200 0 Portsmth Hosp T Ē Ē F Bnmth & Chch FT sle of Wight T Southmptn FT ⁼rimley FT Salisbury FT Hosp [>]oole Hosp Hmpshre Hosp There were over 850 C Dorcet (admissions for ARLD E at the two biggest Trusts in 2015

Trust variation: % of Liver Disease admissions coded with ARLD/alcohol

Key Narrative

In 2015 the percentage of LD admissions coded with ARLD varied by Trusts between 23-42%.

The percentage of LD admissions coded with alcohol-specific conditions ('ARLD' + 'other alcohol') varied by Trust between 30-46%.



Trust variation: HRG spend for alcohol Liver Disease admissions across Wessex


Key Narrative

Cost for each admission were calculated using PbR tariffs.

Note: not all admissions could have a PbR tariff attached. Therefore approximately 10% of admission costs are not accounted for. Poole HFT did not provide HRG data and so no costs are presented.

ARLD admission costs in 2015 for the 9 Trusts totalled almost £5.9 million. The two largest Trusts account for over £2.6 million of this.

The two largest Trusts have a higher proportion of cost associated with LD admissions with alcohol-specific conditions than the other Trusts.



Trust variation: admission breakdown by final Liver Disease diagnosis

Key Narrative


When comparing the last LD diagnosis code of each admission spell in 2015:

The proportion of ARLD diagnoses varied by 17-33% between Trusts.

The proportion of NAFLD/NASH diagnoses varied by 7-37% between Trusts.

Smaller Trusts are observed to have a greater proportion of admissions with a final ARLD diagnosis.

The largest Trust had 60% of LD admissions neither classified as ARLD or NAFLD/NASH.



Trust variation: LOS for (ages 46-65yrs)


Key Narrative

There is variation in LOS for both ARLD and non-ARLD groups between Trusts. Median LOS varies between 5-7 days for non-ARLD diagnosed patients and 6-8 days for ARLD diagnosed patients.

Salisbury FT and Frimley FT have the longest LOS in Wessex for ARLD patients.

Bournemouth and Christchurch FT has on average the lowest LOS for both ARLD and non-ARLD groups.

> Length of Stay is greater for ARLD admissions across all **Trusts in Wessex**



Length of spell for each trust 2015: ARLD and non-ARLD cohorts

CCG variation: number of Liver Disease admissions from CCGs across Wessex

Key Narrative

Note: CCG data only includes the admissions to the 9 Acute NHS Trusts submitting data.

West Hants, Dorset and Southampton CCGs have the greatest numbers of Liver Disease admissions to the 9 NHS Trusts for which data was collected.

Non-Wessex Liver Disease admissions are relatively high mostly due to patients admitted to NE Hampshire & Farnham CCG.

& other LD, by CCG, to 9 Wessex Trusts (2015) 1400 ARLD other alcohol 1200 other LD 1000 no. of admissions 800 600 400 200 0 **Dorset CCG** West Hampshire CCG Southampton CCG Portsmouth CCG Fareham and Gosport CCG South Eastern Hampshire CCG **Vorth Hampshire CCG** non-Wessex sle of Wight CCG Wiltshire CCG Hampshire & Farnham CCG

ШZ


Admission numbers of ARLD, other alcohol

CCG variation: % of Liver Disease admissions coded with ARLD/alcohol

Key Narrative

In 2015 the percentage of LD admissions coded with ARLD varied by CCG between 26-42.5%.

The percentage of LD admissions coded with alcohol-specific conditions ('ARLD' + 'other alcohol') varied by CCG between 31-48%.



Up to 48% of Liver Disease admissions from some CCGs were alcohol-specific

Estimating early intervention cost avoidance in Wessex

- Nuffield Trust report on "Alcohol-specific activity in hospitals in England" (published Dec 2015) showed:
 - rising burden of alcohol on A&E departments (attendance rates doubled between 2008/09-2013/14)
 - highlighted the possibility for earlier
 intervention: ¾ of those diagnosed with ARLD
 during 2009/2010 had contact with hospital
 services the year before diagnosis.

Estimating early intervention cost avoidance in Wessex: current cost

For further detail on the method for the estimated cost avoidance see Appendix D

Key Narrative

The Nuffield Trust report showed the average number of: elective admissions, emergency admissions, A&E attendances and outpatient appointments for ARLD patients before and after first ARLD diagnosis.

There are ~865 new ARLD diagnoses in Wessex each year and the costs of acute treatment for the cohort were estimated using National Schedule of Reference Costs (year 2014-15).

An annual mortality rate of 15.3% is used, as found from the Wessex Trust data examined.

The estimated annual cost of treatment for all ARLD patients at the 9 Acute Trusts is £25.3m.

Current 1st £10,000,000 ARLD diagnosis £9,000,000 £8,000,000 £7,000,000 £6,000,000 £5,000,000 £4,000,000 £3,000,000 £2,000,000 £1,000,000 £--4 -3 -2 3 1 2 Δ Year from ARLD diagnosis Current cost Early intervention cost Cost avoided The estimated annual cost of treatment for all ARLD patients at the 9 Acute Trusts

Estimated (1year) early intervention cost avoidance in Wessex

is £25.3m


Estimating early intervention cost avoidance in Wessex: new cost

For further detail on the method for the estimated cost avoidance see Appendix D

Key Narrative

Assuming earlier intervention prior to current first ARLD diagnosis (and a reduction in annual mortality rate), the subsequent reduction in elective admissions, emergency admissions and A&E attendances (but not outpatient appointments) would result in a reduced cost of managing the patient cohort each year after the earlier diagnosis.

If diagnosis of ARLD patients is brought forward by 1 year the new estimated annual cost of treatment is £12.4m. Bringing this forward by 2 years the estimated cost is £8.1m.



£12.4m per year

Estimating early intervention cost avoidance in Wessex: cost avoided


For further detail on the method for the estimated cost avoidance see Appendix D

Key Narrative

If diagnosis of ARLD patients is brought forward (by either 1 or 2 years) the estimated cost avoidance at the 9 Acute Trusts is between £12.9m-£17.2m per year respectively.

Note: this is likely an under estimate as the figures only include hospitalised costs; costs in additional care settings could further increase the potential costs avoided.

Early intervention requires mandatory alcohol screening and referrals to alcohol care team. The cost of an alcohol team is approximately £150k annually per Trust.




Estimating early intervention cost avoidance in Wessex: where are costs avoided?

Key Narrative

The estimated cost savings from intervening either 1 or 2 years earlier are broken down opposite.

The largest estimated cost avoidance is from emergency admissions (contributing ~68% of cost avoidance), followed by elective admissions (contributing ~28%).

An increase in cost is expected from outpatient appointments (due to the increased patient survival). This cost is relatively small in comparison and is included in the estimated cost avoidance quoted.



cost avoidance

see Appendix D

Breakdown of earlier intervention cost avoidance

	1 year earlier	2 years earlier	
Elective admissions	£3,763,400	£4,805,800	
Emergency admissions	£8,685,100	£11,901,000	
Outpatient appointments	-£108,800	-£108,800	
A&E attendances	£566,700	£566,700	
Total	£12,910,000	£17,160,000	

What must you do for an effective ARLD pathway?

For Providers:

- 1. Implement a Trust alcohol strategy
- 2. Find an alcohol champion at executive level
- 3. Designate a board metric for Alcohol
 - e.g. NICE Alcohol Quality Standard
- 4. Mandatory alcohol screening and referral to alcohol team
 - A Trust alcohol team costs around £150k per annum and consists of: 0.1-0.2 FTE hospital clinical lead

2.0 FTE specialist nurses (one band 7 & one band 5 - mix of MHN and RGN)

1.0 FTE band 3 for alcohol screening

1.0 FTE admin/pathway co-ordinator (for co-ordination and data)

For Commissioners:

- 1. Commission an alcohol pathway that supports earlier intervention
- 2. Ensure that routine monitoring systems are in place to track implementation of the new pathway

Wessex AHSN can offer you:

The Wessex AHSN have developed a toolkit to assist Trusts to implement system wide changes to how patients with ARLD are identified and managed within current resources. This includes:

- an audit protocol
- implementation pack
- training resources
- access to Trust data

...to benchmark their organisation and monitor changes.

For more information please contact: <u>alcohol@wessexahsn.net</u>



Contacts & Acknowledgements

Data and analysis produced by: Dr Anastasios Argyropoulos <u>A.Argyropoulos@soton.ac.uk</u>

Wessex Centre for Implementation Science

Faculty of Health Sciences

University of Southampton

WessexCIS@soton.ac.uk

@WessexCIS

On behalf of Wessex Academic Health Science Network:

UNIVERSITY OF

alcohol@wessexahsn.net

@WessexAHSN

With thanks to:

- Dr Julia Sinclair
- Dr Leonie Grellier
- Cathy Rule
- Kathy Wallis
- Prof Paul Roderick
- Dr Harriet Gordon
- Dr Richard Aspinall
- Dr Safa Al-Shamma
- Dr Nick Sharer
- Matt Winker
- Caroline Powell
- Bill Gillespie





Appendix A: Data definitions & limitations

Definitions:

- Liver Disease (LD) admissions were identified as: any admission with an ICD-10 diagnosis starting with 'K7' (anywhere within episode). See Appendix B for full list.
- Alcohol Related Liver Disease (ARLD) admissions were identified as: any admission with an ICD-10 diagnosis starting with 'K70' (anywhere within episode)
- Alcohol-specific LD admissions were identified with the same methodology as in the Local Alcohol Profiles England produced by PHE: any LD admission with an ICD-10 diagnosis within the list seen in Appendix C (anywhere within episode)

Limitations:

- Records are not linked between Trusts, hence the same patient may receive treatment at multiple Trusts but will be recorded as a separate individual within this dataset and corresponding analyses
- Any calculation involving a death involves only the deaths recorded on the Trust database (i.e. some deaths outside of the hospital may not be recorded)
- Although in some analyses patients are separated into ARLD/non-ARLD groups it is likely that there will always be patients in the non-ARLD group who in fact have not yet been diagnosed with ARLD
- PbR costs are not presented for one Trust as insufficient data was provided to calculate this. Of the admissions with suitable data 10% of the admissions could not have a PbR cost calculated (hence estimates of the total cost could be around 10% smaller than presented)

Appendix B: ICD-10 Liver Disease diagnosis codes (1/3)

ICD-10 code	Description
К70	Alcoholic liver disease
К70.0	Alcoholic fatty liver
K70.1	Alcoholic hepatitis
К70.2	Alcoholic fibrosis and sclerosis of liver
K70.3	Alcoholic cirrhosis of liver
K70.4	Alcoholic hepatic failure
K70.9	Alcoholic liver disease, unspecified
K71	Toxic liver disease
K71.0	Toxic liver disease with cholestasis
K71.1	Toxic liver disease with hepatic necrosis
K71.2	Toxic liver disease with acute hepatitis
K71.3	Toxic liver disease with chronic persistent hepatitis
K71.4	Toxic liver disease with chronic lobular hepatitis
K71.5	Toxic liver disease with chronic active hepatitis
K71.6	Toxic liver disease with hepatitis, not elsewhere classified
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver
K71.8	Toxic liver disease with other disorders of liver
K71.9	Toxic liver disease, unspecified
K72	Hepatic failure, not elsewhere classified
К72.0	Acute and subacute hepatic failure
K72.1	Chronic hepatic failure
К72.9	Hepatic failure, unspecified





Appendix B: ICD-10 Liver Disease diagnosis codes (2/3)

ICD-10 code	Description
К73	Chronic hepatitis, not elsewhere classified
к73.0	Chronic persistent hepatitis, not elsewhere classified
K73.1	Chronic lobular hepatitis, not elsewhere classified
K73.2	Chronic active hepatitis, not elsewhere classified
К73.8	Other chronic hepatitis, not elsewhere classified
к73.9	Chronic hepatitis, unspecified
К74	Fibrosis and cirrhosis of liver
К74.0	Hepatic fibrosis
K74.1	Hepatic sclerosis
К74.2	Hepatic fibrosis with hepatic sclerosis
K74.3	Primary biliary cirrhosis
K74.4	Secondary biliary cirrhosis
K74.5	Biliary cirrhosis, unspecified
К74.6	Other and unspecified cirrhosis of liver
К75	Other inflammatory liver diseases
K75.1	Phlebitis of portal vein
К75.2	Nonspecific reactive hepatitis
K75.3	Granulomatous hepatitis, not elsewhere classified
K75.4	Autoimmune hepatitis
K75.8	Other specified inflammatory liver diseases: Nonalcoholic steatohepatitis [NASH]
К75.9	Inflammatory liver disease, unspecified



Source: WHO ICD-10 classifications <u>attp://apps.who.int/classifications/icd10/browse/2016/en#/K70-K77</u>

Appendix B: ICD-10 Liver Disease diagnosis codes (3/3)

ICD-10 code	Description
к76	Other diseases of liver
К76.0	Fatty (change of) liver, not elsewhere classified (Non-alcoholic fatty liver disease [NAFLD])
K76.1	Chronic passive congestion of liver
К76.2	Central haemorrhagic necrosis of liver
К76.3	Infarction of liver
К76.4	Peliosis hepatis
К76.5	Hepatic veno-occlusive disease
К76.6	Portal hypertension
К76.7	Hepatorenal syndrome
К76.8	Other specified diseases of liver
К76.9	Liver disease, unspecified
K77*	Liver disorders in diseases classified elsewhere
K77.0*	Liver disorders in infectious and parasitic diseases classified elsewhere
K77.8*	Liver disorders in other diseases classified elsewhere

Source: WHO ICD-10 classifications <u>http://apps.who.int/classifications/icd10/browse/2016/en#/K70-K77</u>



Appendix C: Wholly alcohol attributable ICD-10 codes used to define alcohol-specific inpatient activity (alcohol-specific conditions)

ICD-10 code	Description
E24.4	Alcohol-induced pseudo-Cushing's syndrome
F10	Mental and behavioural disorders due to alcohol
G31.2	Degeneration of nervous system due to alcohol
G62.1	Alcoholic polyneuropathy
G72.1	Alcoholic myopathy
142.6	Alcoholic cardiomyopathy
К29.2	Alcoholic gastritis
к70	Alcoholic liver disease
K85.2	Alcohol-induced acute pancreatitis
К86.0	Alcohol-induced chronic pancreatitis
Q86.0	Foetal alcohol syndrome (dysmorphic)
R78.0	Excess alcohol blood levels
T51.0	Ethanol poisoning
T51.1	Methanol poisoning
T51.9	Toxic effect of alcohol, unspecified
X45	Accidental poisoning by and exposure to alcohol
X65	Intentional self-poisoning by and exposure to alcohol, undetermined intent
Y15	Poisoning by and exposure to alcohol, undetermined intent
Y90	Evidence of alcohol involvement determined by blood alcohol content
Y91	Evidence of alcohol involvement determined by level of intoxication

Source: PHE England Local Alcohol Profiles User Guide

Appendix D: Estimating early intervention cost avoidance in Wessex (1/7)

Introduction

The estimation of 'early intervention cost avoidance in Wessex' was calculated using data from a variety of sources:

- Wessex AHSN Acute Liver Disease database
- *"Alcohol-specific activity in hospitals in England"* (2015), Nuffield Trust report
- NHS reference costs 2014 to 2015*
- *"The Epidemiology of Alcoholic Liver Disease"* (2004), Mann R.E., Smart, R.G. & Govoni, R., Publication from the National Institute on Alcohol Abuse and Alcoholism

The method and assumptions made in the calculations are outlined in this appendix. The inputs and assumptions within the cost estimation model are summarised in the following slide with further detail surrounding the method following. All **cost estimates are at 2014/15 values**.

Appendix D: Estimating early intervention cost avoidance in Wessex (2/7)

'Current cost' model inputs

Model input	Value	Source/comments
Initial size of ARLD cohort	865 (Wessex), varies by Trust	Source: Wessex AHSN Acute Liver Disease database (2011-2015). Data showed ~865 patients each year between 2011-15 were newly diagnosed with ARLD in Wessex.
Annual mortality rate	Fixed annual rate of 15.3%	Source: as above. Annual rate calculated from the 4-year survival probability (51.4%) of ARLD patients who had first ARLD diagnosis in 2012. Note: deaths only include those recorded on Trust data systems.
Average additional utilisation rate of secondary care services by ARLD patients: 4-years before and after ARLD diagnosis		Source: "Alcohol-specific activity in hospitals in England" (2015), Nuffield Trust report
Average cost of: elective admissions, emergency admissions, A&E attendances and outpatient appointments	Fixed cost based on 2014/15 prices (values in Appendix D: 5/7)	Source: NHS reference costs 2014 to 2015


'New cost' model inputs

Model input	Value	Source/comments
Initial size of ARLD cohort	by Trust	Source: Wessex AHSN Acute Liver Disease database (2011-2015). Data showed ~865 patients each year between 2011-15 were newly diagnosed with ARLD in Wessex.
Annual mortality rate	Fixed annual rate of 2.1%	Source: "The Epidemiology of Alcoholic Liver Disease" (2004), Mann R.E., Smart, R.G. & Govoni, R., Publication from the National Institute on Alcohol Abuse and Alcoholism. Annual rate calculated from the 5-year survival probability (90%) of those with cirrhosis who stop drinking.
Average additional utilisation rate of secondary care services by ARLD patients: 4-years before and after ARLD diagnosis	year from ARLD diagnosis (values in	Source: "Alcohol-specific activity in hospitals in England" (2015), Nuffield Trust report. Modifications to the additional utilisation rates, reported by the Nuffield Trust, were made with the assumption that earlier diagnosis will lead to an earlier reduction in additional utilisation rates.
Average cost of: elective admissions, emergency admissions, A&E attendances and outpatient appointments	Fixed cost based on 2014/15 prices (values in Appendix D: 5/7)	Source: NHS reference costs 2014 to 2015

Appendix D: Estimating early intervention cost avoidance in Wessex (3/7)

Additional hospital usage of ARLD patients

The average hospital activity for ARLD diagnosed patients (above that of the average population) was taken from the Nuffield Trust Report (2015). This showed the average: elective admissions, emergency admissions, A&E attendances and outpatient appointments for ARLD patients before and after their first ARLD diagnosis. A summary of the additional activity as an 'age, sex & deprivation standardised rate per capita' is shown below (left). The 'current cost' estimates are based on this additional hospital utilisation rate. An assumption that earlier diagnosis will lead to a reduction in: elective admissions, emergency admissions and A&E attendances (but not outpatient appointments) is used. An annual reduction in the activity rate of 33% is assumed. The altered additional hospital utilisation (for diagnosis 1 year earlier) is shown below (right). This hospital utilisation is used for the 'new cost' estimations.



Appendix D: Estimating early intervention cost avoidance in Wessex (4/7)

Number of new diagnoses per year & mortality assumptions

The number of the newly diagnosed Wessex ARLD patients was identified from the Wessex AHSN Liver Disease database. There are ~865 new ARLD diagnoses at the 9 Acute Trusts in Wessex each year (2011-2015). The Wessex Trust data examined showed a 4-year survival rate of 51.4% (equal to an annual mortality rate of 15.3%). This survival rate is calculated only from the deaths known to the Trusts. This was used in the estimation of the 'current cost'.

Mann *et al* (2004) states the 5-year survival rate of cirrhosis patients who stop drinking as 90% (equal to an annual mortality rate of 2.1%). This value is used to estimate the cohort size in the 'new cost' estimation. This is thought to be a 'best case' survival rate and hence will produce a more conservative estimate of the possible cost avoidance (a smaller cohort being alive will result in lower service utilisation). The summary of the estimated cohort changes over time is shown in the table below.

						Diagnosis				
	Year	-4	-3	-2	-1	1	2	3	4	Annual mortality
CURRENT Patient Cohort	865	865	865	865	865	733	621	526	446	15.3%
NEW Cohort	865	865	865	865	865	847	830	813	797	2.1%

Appendix D: Estimating early intervention cost avoidance in Wessex (5/7)

Estimating additional hospital activity of ARLD patients and costs associated

The total additional hospital activity was calculated from the average additional activity rate multiplied by the number of patients alive in each year. The total cost of treatment was then calculated using average National Schedule of Reference Costs (Year: 2014/15) for: elective admissions, emergency admissions, A&E attendances and outpatient appointments. Costs used are shown in the table (right).

This was completed for the 'current cost' and 'new cost', which were then compared to give an estimated 'cost avoidance'. The summary table of calculations is given in the following slide.

Average cost calculations: National schedule of reference costs

The reference costs are: the average unit cost to the NHS of providing secondary healthcare to NHS patients and are used to set prices for NHS-funded services in England.

The calculated average elective and non-elective admission costs were weighted by activity after the exclusion of tariff costs for: Labour and delivery incl. C-sections, Neonatal, Paediatric & Under 18 years. Non-elective long-stay and non-elective short-stay costs were weighted by activity in order to calculate an average emergency admission cost.

The average costs for A&E attendances and outpatient appointments were not weighted by activity. No exclusions were made to the A&E tariffs. The average cost for outpatient appointments was calculated from the hepatology treatment function only.

Source: National Schedule of Reference Costs Year : 2014-15Elective admission£ 3,945Emergency admission£ 2,320

Emergency admission	£	2,320
Outpatient appointment	£	178
A&E attendance	£	127



Appendix D: Estimating early intervention cost avoidance in Wessex (6/7)

The tabulated hospital activity and costs for the cohort, in the four years prior and the four years following ARLD diagnosis, are summarised below. In this example the 'new cost' is based on the 1-year earlier diagnosis of patients.

CURRENT ADDITIONAL COST													
Year from current 1st diagnosis		-4		-3	-2		-1	1		2	3	4	Tota
Addional elective admissions		115	1	14	195		654	312		166	88	57	
Additional emergency admissions		415	5	30	905		2,738	1,052		687	441	324	
Additional outpatient appointments		750	8	36	1,038		1,615	1,038		621	272	118	
Additional A&E attendances		-	-		579		1,976	1,382		973	614	476	
Spending estimate	£	1,551,695	£ 2,064,0	73 £	3,125,458	£	9,469,224	£ 4,029,739	£	2,483,183 £	1,495,649	£ 1,059,727 £	25,278,74
Addional elective admissions	£	454,990	£ 568,7	38 £	767,796	£	2,578,277	£ 1,228,966	£	655,694 £	345,845	£ 226,218	
Additional emergency admissions	£	963,264	£ 1,346,4	98 £	2,099,422	£	6,352,560	£ 2,440,391	£	1,593,393 £	1,023,494	£ 752,162	
Additional outpatient appointments	£	133,441	£ 148,8	38 £	184,764	£	287,411	E 184,838	£	110,538 £	48,374	£ 20,930	
Additional A&E attendances	£	-	£ -	£	73,477	£	250,976	£ 175,543	£	123,558 £	77,936	£ 60,418	
ESTIMATED NEW COST													
Year from current 1st diagnosis		-4		-3	-2		-1	1		2	3	4	Tota
Addional elective admissions		115	1	14	195		128	83		54	35	22	
Additional emergency admissions		415	5	30	905		597	386		250	161	104	
Additional outpatient appointments		750	8	36	1,038		1,615	1,200		830	420	210	
Additional A&E attendances		-	-		579		382	247		160	103	67	
Spending estimate	£	1,551,695	£ 2,064,0	73 £	3,125,458	£	2,228,269	E 1,467,896	£	958,969 £	599,214	£ 376,723 £	12,372,29
Addional elective admissions	£	454,990	£ 568,7	38 £	767,796	£	506,745	£ 327,492	£	211,807 £	136,929	£ 88,595	
Additional emergency admissions	£	963,264	£ 1,346,4	98 £	2,099,422	£	1,385,618	£ 895,478	£	579,153 £	374,412	£ 242,249	
Additional outpatient appointments	£	133,441	£ 148,8	38 £	184,764	£	287,411	£ 213,585	£	147,740 £	74,769	£ 37,401	
Additional A&E attendances	£	-	£ -	£	73,477	£	48,495	£ 31,340	£	20,270 £	13,104	£ 8,478	
COST AVOIDED	£	-	6	£	-	2	7,240,955	£ 2,561,843	£	1,524,214 £	896,435	£ 683,004 £	12,906,452

Appendix D: Estimating early intervention cost avoidance in Wessex (7/7)

The total: 'current cost', 'new cost' and 'cost avoided' estimations for the cohort over the 8 years is given in the table below for the assumption of diagnosing patients both 1-year and 2-years earlier.

	CURRENT COST			NEW COST	COST AVOIDED		
Diagnosis 1-year earlier	£	25,278,748	£	12,372,296	£	12,906,452	
Diagnosis 2-years earlier	£	25,278,748	£	8,114,094	£	17,164,654	

Total 8-year estimated treatment costs associated with earlier diagnosis of ARLD

These values are the same as the annual cost if all ARLD patients (not just a single cohort) at the 9 Acute Trusts in Wessex were managed in the same way. It is therefore estimated that **across the 9 Acute Trusts there is a potential cost avoidance of between £12.9m - £17.2m per year** through the earlier diagnosis and management of ARLD patients.

Note: this is likely to be an under estimate of total cost as the figures only include hospitalised costs; reduced costs in additional care settings could further increase the potential costs avoided with earlier diagnosis.